全膝关节置换术后3年慢性疼痛与功能结局及围手术期地塞米松:随机临床试验DEX-2-TKA的随访
本研究为DEX-2-TKA随机临床试验的3年随访,旨在评估全膝关节置换术后静脉给予1剂(DX1)或2剂(DX2)24 mg地塞米松或安慰剂对疼痛、躯体功能和健康相关生活质量的影响。结果显示,DX2组、DX1组和安慰剂组在40米快速步行等测试中的峰值疼痛强度中位数均为0,组间无显著差异(P=0.72),次要结局亦无差异。结论认为,1或2剂24 mg地塞米松未影响全膝关节置换术后3年慢性疼痛的发生或躯体功能。
要点
- 在全膝关节置换术后3年随访中,DX2组、DX1组和安慰剂组的峰值疼痛强度中位数均为0(P=0.72),组间无显著差异。
- 静脉给予1或2剂24 mg地塞米松未影响全膝关节置换术后3年慢性疼痛的发生或躯体功能。
- 次要结局(包括牛津膝关节评分、EQ5D5L、PainDetect及多项功能测试)在各组间均未发现差异。
核心结论
- 静脉给予1或2剂24 mg地塞米松未影响全膝关节置换术后3年慢性疼痛的发生或躯体功能。
研究设计与样本
- 本研究为随机临床试验DEX-2-TKA的3年随访,纳入符合条件患者252例,其中133例(52.8%)完成功能测试,160例(63.5%)完成问卷。
- 干预为静脉给予1剂(DX1)或2剂(DX2)24 mg地塞米松或安慰剂,随访平均33个月(范围23至40个月)。
- 主要结局为40米快速步行测试、计时起立-行走测试、30秒坐立测试和爬楼测试期间的平均峰值疼痛强度,采用0至100毫米视觉模拟量表评估。
主要发现
- 峰值疼痛强度中位数(四分位距)为DX2组0(0至65)、DX1组0(0至51)、安慰剂组0(0至70),组间比较P=0.72。
- 次要结局(包括功能测试和问卷)在各组间均未发现差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative dexamethasone as an adjunct to multimodal analgesia, has an opioid-sparing and pain alleviating effect after total knee arthroplasty (TKA), however, the 3-year effects are unknown. We aimed to investigate the 3-year effect of 1 (DX1) or 2 (DX2) intravenous doses of 24 mg dexamethasone or placebo on pain, physical function, and health-related quality of life after TKA. METHODS: Patients who participated in the Dexamethasone Twice for Pain Treatment after TKA (DEX-2-TKA) were invited to physical tests and questionnaires (self-reported characteristics, Oxford Knee Score, EuroQol-5Dimensions-5Levels (EQ5D5L), and PainDetect). The tests were 40-meter Fast Paced Walk (40FPW) test, Timed Up and Go (TUG), 30 Second Chair Stand test (30CST), Stair Climb Test (SCT), bilateral knee Range of Motion, and knee extension torque. For each test the peak pain intensity was registered on a 0 to 100 mm Visual Analogue Scale. Primary outcome was average peak pain intensity during the 40FPW, TUG, 30CST and SCT. Secondary outcomes were the tests and questionnaires. Out of 252 eligible patients, 133 (52.8%) underwent the tests and 160 (63.5%) answered the questionnaires. Mean follow-up time was 33 months (range, 23 to 40). RESULTS: Median (interquartile range) peak pain intensity was 0 (0 to 65) for the DX2 group, 0 (0 to 51) for DX1 group and 0 (0 to 70) for the placebo group (P = .72). No differences in secondary outcomes were identified. CONCLUSION: One or 2 intravenous doses of 24 mg dexamethasone did not impact chronic pain development or physical function 3 years after TKA.
引用
- Mølgaard AK, Gasbjerg KS, Skou ST, et al. Chronic Pain and Functional Outcome 3 years After Total Knee Arthroplasty and Perioperative Dexamethasone: A Follow-Up of the Randomized, Clinical DEX-2-TKA Trial. J Arthroplasty. 2023. PMID: 37286048. doi:10.1016/j.arth.2023.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。